Publications

Export 1318 results:
Sort by: Author Title [ Type  (Desc)] Year
Journal Article
AlKhoori, A. A., K. Polychronopoulou, A. Belabbes, M. A. Jaoude, L. F. Vega, V. Sebastian, S. Hinder, M. A. Baker, and A. F. Zedan, "Cu, Sm co-doping effect on the CO oxidation activity of CeO2. A combined experimental and density functional study", Applied Surface Science, vol. 521: Elsevier, pp. 146305, 2020. Abstract
n/a
AlKhoori, A. A., K. Polychronopoulou, A. Belabbes, M. A. Jaoude, L. F. Vega, V. Sebastian, S. Hinder, M. A. Baker, and A. F. Zedan, "Cu, Sm co-doping effect on the CO oxidation activity of CeO2. A combined experimental and density functional study", Applied Surface Science, vol. 521: Elsevier, pp. 146305, 2020. Abstract

n/a

AlKetbi, M., K. Polychronopoulou, M. A. Jaoude, M. A. Vasiliades, V. Sebastian, S. J. Hinder, M. A. Baker, A. F. Zedan, and A. M. Efstathiou, "Cu-Ce-La-Ox as efficient CO oxidation catalysts: Effect of Cu content", Applied Surface Science, vol. 505: Elsevier, pp. 144474, 2020. Abstract
n/a
AlKetbi, M., K. Polychronopoulou, M. A. Jaoude, M. A. Vasiliades, V. Sebastian, S. J. Hinder, M. A. Baker, A. F. Zedan, and A. M. Efstathiou, "Cu-Ce-La-Ox as efficient CO oxidation catalysts: Effect of Cu content", Applied Surface Science, vol. 505: Elsevier, pp. 144474, 2020. Abstract

n/a

Cachia, R., Aldaoud, M., Eldeib, Hiari, O., Tweissi, A., Villar-Onrubia, D., Wimpenny, K., and I. Maya-Jariego, "Cultural diversity in the adoption of open education in the Mediterranean basin: collectivist values and power distance in the universities of the Middle East", Araucaria-Latin American journal of policy and international relations, vol. 44, issue 22, pp. 53-82, 2020.
Ashour, I. S., E. L. K. A. D. I. HATEM, K. H. A. L. E. D. SHERIF, J. - P. Vilcot, and D. Decoster, "Cutoff frequency and responsivity limitation of AlInAs/GaInAs MSM PD using a two dimensional bipolar physical model", IEEE transactions on electron devices, vol. 42, no. 2: Institute of Electrical and Electronics Engineers, pp. 231–238, 1995. Abstract
n/a
Vassen, W., E. A. J. M. Bente, and W. Hogervorst, "CW laser excitation of the barium 6sng and 6snh Rydberg series from the metastable 6s5d 1.3 D and 5d2 1G4 states", Journal of Physics B: Atomic and Molecular Physics, vol. 20, no. 11: IOP Publishing, pp. 2383, 1987. Abstract
n/a
Elgebaly, S. A., C. Van Buren, R. Todd, R. Poston, R. K. Arafa, N. El-Khazragy, D. Kreutzer, M. A. Rabie, A. F. Mohamed, L. A. Ahmed, et al., "Cyclocreatine Phosphate: A Novel Bioenergetic/Anti-Inflammatory Drug That Resuscitates Poorly Functioning Hearts and Protects against Development of Heart Failure.", Pharmaceuticals (Basel, Switzerland), vol. 16, issue 3, 2023. Abstract

Irreversible myocardial injury causes the exhaustion of cellular adenosine triphosphate (ATP) contributing to heart failure (HF). Cyclocreatine phosphate (CCrP) was shown to preserve myocardial ATP during ischemia and maintain cardiac function in various animal models of ischemia/reperfusion. We tested whether CCrP administered prophylactically/therapeutically prevents HF secondary to ischemic injury in an isoproterenol (ISO) rat model. Thirty-nine rats were allocated into five groups: control/saline, control/CCrP, ISO/saline (85 and 170 mg/kg/day s.c. for 2 consecutive days), and ISO/CCrP (0.8 g/kg/day i.p.) either administrated 24 h or 1 h before ISO administration (prophylactic regimen) or 1 h after the last ISO injection (therapeutic regimen) and then daily for 2 weeks. CCrP protected against ISO-induced CK-MB elevation and ECG/ST changes when administered prophylactically or therapeutically. CCrP administered prophylactically decreased heart weight, hs-TnI, TNF-α, TGF-β, and caspase-3, as well as increased EF%, eNOS, and connexin-43, and maintained physical activity. Histology indicated a marked decrease in cardiac remodeling (fibrin and collagen deposition) in the ISO/CCrP rats. Similarly, therapeutically administered CCrP showed normal EF% and physical activity, as well as normal serum levels of hs-TnI and BNP. In conclusion, the bioenergetic/anti-inflammatory CCrP is a promising safe drug against myocardial ischemic sequelae, including HF, promoting its clinical application to salvage poorly functioning hearts.

Elmonem, M. A., K. R. Veys, N. A. Soliman, M. van Dyck, L. P. van den Heuvel, and E. Levtchenko, "Cystinosis: a review.", Orphanet journal of rare diseases, vol. 11, pp. 47, 2016. Abstract

Cystinosis is the most common hereditary cause of renal Fanconi syndrome in children. It is an autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene encoding for the carrier protein cystinosin, transporting cystine out of the lysosomal compartment. Defective cystinosin function leads to intra-lysosomal cystine accumulation in all body cells and organs. The kidneys are initially affected during the first year of life through proximal tubular damage followed by progressive glomerular damage and end stage renal failure during mid-childhood if not treated. Other affected organs include eyes, thyroid, pancreas, gonads, muscles and CNS. Leucocyte cystine assay is the cornerstone for both diagnosis and therapeutic monitoring of the disease. Several lines of treatment are available for cystinosis including the cystine depleting agent cysteamine, renal replacement therapy, hormonal therapy and others; however, no curative treatment is yet available. In the current review we will discuss the most important clinical features of the disease, advantages and disadvantages of the current diagnostic and therapeutic options and the main topics of future research in cystinosis.

Amin, R. M., A. Abdelmem, T. Verwanger, E. S. E. Sayed, and B. Krammer, "Cytotoxcicity of Magnetic Nanoparticles on Normal and Malignant Human Skin Cells ", Nano LIFE: World Scientific Publishing Company, 2013. Abstract

n/a

Sabry, O. M. M., D. E. Goeger, F. A. Valeriote, and W. H. Gerwick, "Cytotoxic halogenated monoterpenes from Plocamium cartilagineum", Natural product research, vol. 31, issue 3 , pp. 261-267, 2016. cytotoxic_halogenated_monoterpenes_from_plocamium_cartilagineum.pdf
Sabry, O. M. M., D. E. Goeger, F. A. Valeriote, and W. H. Gerwick, "Cytotoxic halogenated monoterpenes from Plocamium cartilagineum", Natural product research., vol. 31, issue (3), pp. 261-267, 2017. cytotoxic_halogenated_monoterpenes_from_plocamium_cartilagineum.pdf
Amin, R. M., A. B. U. E. L. M. A. G. D. ABDELMONEM, T. Verwanger, E. L. S. A. Y. E. D. ELSHERBINI, and B. Krammer, "CYTOTOXICITY OF MAGNETIC NANOPARTICLES ON NORMAL AND MALIGNANT HUMAN SKIN CELL", World Scienti¯c Publishing, vol. 4,, issue 1, pp. (8 , 2013. 12.pdf
Hézode, C., G. M. Hirschfield, W. Ghesquiere, W. Sievert, M. Rodriguez-Torres, S. D. Shafran, P. J. Thuluvath, H. A. Tatum, I. Waked, G. Esmat, et al., "Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.", Gut, 2014 Jul 30. Abstract

OBJECTIVE: To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin.

DESIGN: In this Phase 2b double-blind, placebo-controlled study, treatment-naive adults with HCV genotype 1 (N=365) or 4 (N=30) infection were randomly assigned (2:2:1) to daclatasvir 20 mg or 60 mg, or placebo once daily plus weekly peginterferon-alfa-2a and twice-daily ribavirin. Daclatasvir recipients achieving protocol-defined response (PDR; HCV-RNA

Hezode, C., G. M. Hirschfield, W. Ghesquiere, W. Sievert, M. Rodriguez-Torres, S. D. Shafran, P. J. Thuluvath, H. A. Tatum, I. Waked, G. E. Esmat, et al., "Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive HCV-Genotype 1 or 4 Subjects: Phase 2b COMMAND-1 SVR12 Results", HEPATOLOGY, vol. 56, no. 1}, Meeting Abstract = {755, pp. 553A-554A, OCT, 2012. Abstract
n/a
K., A., J. Lopez-Moreno, M. McCabe, S. M. Robaa, F. Domínguez-Castro, M. Peña-Gallardo, R. M. Trigo, M. E. Hereher, and S. M. VICENTE-SERRANO, "Daily temperature extremes over Egypt: spatial patterns, temporal trends, and driving forces", ATMOSPHERIC RESEARCH, vol. 226 , pp. 219–239, 2019. Ahmed_et_al._2019.pdf
Vilay, M. A., M. Grio, D. D. DePestel, K. M. Sowinski, L. Gao, M. Heung, N. N. Salama, and B. A. Mueller, "Daptomycin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis", Critical Care Medicine, vol. 39, issue 1, 2011. Abstract

Objective: To investigate daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis to develop dosing recommendations.

Antucheviciene, J., Z. Kala, M. Marzouk, and E. Vaidogas, "Decision Making Methods and Applications in Civil Engineering", Mathematical Problems in Engineering, vol. 2015, pp. 1-3, 2015.
Kaur, D., T. Behl, A. Sehgal, S. Singh, N. Sharma, S. Chigurupati, A. Alhowail, A. Abdeen, S. F. Ibrahim, C. Vargas-De-La-Cruz, et al., "Decrypting the potential role of α-lipoic acid in Alzheimer's disease", Life Sciences, vol. 284, issue 2021, pp. 119899, 2021.
Pennell, D. J., J. B. Porter, M. D. Cappellini, L. L. Chan, A. El-Beshlawy, Y. Aydinok, H. Ibrahim, C. - K. Li, V. Viprakasit, M. S. Elalfy, et al., "Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.", Haematologica, vol. 97, issue 6, pp. 842-8, 2012 Jun. Abstract

BACKGROUND: Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important.

DESIGN AND METHODS: Seventy-one patients in the EPIC cardiac substudy elected to continue into the 3(rd) year, allowing cardiac iron removal to be analyzed over three years.

RESULTS: Mean deferasirox dose during year 3 was 33.6 ± 9.8 mg/kg per day. Myocardial T2*, assessed by cardiovascular magnetic resonance, significantly increased from 12.0 ms ± 39.1% at baseline to 17.1 ms ± 62.0% at end of study (P<0.001), corresponding to a decrease in cardiac iron concentration (based on ad hoc analysis of T2*) from 2.43 ± 1.2 mg Fe/g dry weight (dw) at baseline to 1.80 ± 1.4 mg Fe/g dw at end of study (P<0.001). After three years, 68.1% of patients with baseline T2* 10 to <20 ms normalized (≥ 20 ms) and 50.0% of patients with baseline T2* >5 to <10 ms improved to 10 to <20 ms. There was no significant variation in left ventricular ejection fraction over the three years. No deaths occurred and the most common investigator-assessed drug-related adverse event in year 3 was increased serum creatinine (n = 9, 12.7%).

CONCLUSIONS: Three years of deferasirox treatment along with a clinically manageable safety profile significantly reduced cardiac iron overload versus baseline and normalized T2* in 68.1% (32 of 47) of patients with T2* 10 to <20 ms.

Mittal, P., A. Saharan, R. Verma, F. M. A. Altalbawy, M. A. Alfaidi, G. E. - S. Batiha, W. Akter, R. K. Gautam, M. S. Uddin, and M. S. Rahman, "Dendrimers: A New Race of Pharmaceutical Nanocarriers", BioMed Research International, vol. 16, pp. 1-11, 2021. farag_1.pdf
Musa, A., J. Ashraf, F. - J. Tsai, S. A. Magd, C. Liu, H. Hussain, E. Voslarova, M. A. Khalil, K. B. Wolitzky-Taylor, D. Lee, et al., "Depression Severity and Depression Stigma Among Students: A Survey of Universities in Five Countries", The Journal of Nervous and Mental Disease, vol. 208, issue 11, 2020. AbstractWebsite

In the university setting, mental disorders have come under greater scrutiny and more attention has been given toward addressing the social stigmas associated with mental illness in an effort to promote mental well-being and improve mental health care delivery on-campus. Depression has been previously linked to a reduction in quality of life, suicidal ideation, and poor academic performance. However, few studies have directly compared the burden of depression or stigmatized views between multiple universities. As a result, this cross-sectional study of university students from five countries was performed to determine the burden of depressive disorders, the stigmatizations of beliefs related to depression, and international variation. A questionnaire consisting of a sociodemographic survey, Patient Health Questionnaire-9 (PHQ-9), and Depression Stigma Scale (DSS) was distributed via multiple routes to undergraduate and graduate students at institutions in the United States, Taiwan, United Arab Emirates, Egypt, and Czech Republic. The point prevalence of depression was determined by using the algorithm scoring method of the PHQ-9. Depression severity was determined according to the summed-item scoring method of the PHQ-9. The degree of stigmatization of beliefs was determined by continuous scores on the DSS subscales for personal and perceived stigma. Differences in depression severity, personal stigma, and perceived stigma were determined according to analysis of variance and further studied using post hoc Tukey's tests. Responses were collected from students in the United States (n = 593), United Arab Emirates (n = 134), Taiwan (n = 217), Egypt (n = 105), and Czech Republic (n = 238). Of 1287 responses, 30.7% (n = 396) screened positive for a depressive disorder: 18.0% (n = 232) for major depressive disorder and 12.7% (n = 164) for another depressive disorder. Depression severity differed internationally (p < 0.001). Emirati students significantly exhibited most depression followed by Czech, American, and Taiwanese students (all ps < 0.001). There was also a difference between students of different countries in terms of personal stigma (p < 0.001), with Emirati students holding more stigmatized personal views than Czech, American, Egyptian, and Taiwanese students (all ps < 0.001). Students similarly demonstrated differences in terms of personal stigma (p < 0.001). Egyptian students exhibited the most perceived stigma followed by Emirati, Taiwanese, American, and Czech students (all ps < 0.001). These findings suggest a high point prevalence of depression among university students and differences in the severity of depression, which has implications for the delivery of mental health care in this population. There were significant differences in terms of personal and perceived stigma between university students, indicating resource allocation for university-based campaigns to reduce depression stigma may need to be tailored to the population. After implementation of stigma reduction programs, future follow-up surveys can be done to compare degrees of stigma before and after the intervention.

Mohammed-Saeid, W., R. Soudy, R. Tikoo, K. Kaur, R. E. Verrall, and I. Badea, "Design and Evaluation of Gemini Surfactant-Based Lipoplexes Modified with Cell-Binding Peptide for Targeted Gene Therapy in Melanoma Model.", Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, vol. 21, issue 1, pp. 363-375, 2018. Abstract

Purpose Achieving successful gene therapy requires delivery of a gene vector specifically to the targeted tissue with efficient expression and a good safety profile. The objective of this work was to develop, characterize and determine if a novel gemini surfactant-based lipoplex systems, modified with a cancer-targeting peptide p18-4, could serve this role. Methods The targeting peptide p18-4 was either chemically coupled to a gemini surfactant backbone or physically co-formulated with the lipoplexes. The influence of targeting ligand and formulation strategies on essential physicochemical properties of the lipoplexes was evaluated by dynamic light scattering and small angle X-ray scattering techniques. In vitro transfection activity and cellular toxicity of lipoplexes were assessed in a model human melanoma cell line. Results All lipoplexes zeta potential and particle size were optimal for cellular uptake and physical stability of the system. The lipoplexes adopted an inverted-hexagonal lipid arrangement. The lipoplexes modified with the peptide showed no significant changes in physicochemical properties or lipoplex assembly. The modification of the lipoplexes with the targeting peptide significantly enhanced protein expression 2-6 fold compared to non-modified lipoplexes. In addition, p18-4 modified lipoplexes significantly improved the safety of the lipoplexes. The ability of the p18-4 modified lipoplexes to selectively express the model protein was confirmed by using healthy human epidermal keratinocytes (HEKa). Conclusion The gemini surfactant-based lipoplexes modified with p18-4 peptide showed significantly higher efficiency and safety compared to the system that did not contain a cancer targeting peptide and provided evidence for their potential application to achieve targeted melanoma gene therapy.

Mohammed-Saeid, W., R. Soudy, R. Tikoo, K. Kaur, R. E. Verrall, and I. Badea, "Design and Evaluation of Gemini Surfactant-Based Lipoplexes Modified with Cell-Binding Peptide for Targeted Gene Therapy in Melanoma Model.", Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, vol. 21, issue 1, pp. 363-375, 2018. Abstract

Purpose Achieving successful gene therapy requires delivery of a gene vector specifically to the targeted tissue with efficient expression and a good safety profile. The objective of this work was to develop, characterize and determine if a novel gemini surfactant-based lipoplex systems, modified with a cancer-targeting peptide p18-4, could serve this role. Methods The targeting peptide p18-4 was either chemically coupled to a gemini surfactant backbone or physically co-formulated with the lipoplexes. The influence of targeting ligand and formulation strategies on essential physicochemical properties of the lipoplexes was evaluated by dynamic light scattering and small angle X-ray scattering techniques. In vitro transfection activity and cellular toxicity of lipoplexes were assessed in a model human melanoma cell line. Results All lipoplexes zeta potential and particle size were optimal for cellular uptake and physical stability of the system. The lipoplexes adopted an inverted-hexagonal lipid arrangement. The lipoplexes modified with the peptide showed no significant changes in physicochemical properties or lipoplex assembly. The modification of the lipoplexes with the targeting peptide significantly enhanced protein expression 2-6 fold compared to non-modified lipoplexes. In addition, p18-4 modified lipoplexes significantly improved the safety of the lipoplexes. The ability of the p18-4 modified lipoplexes to selectively express the model protein was confirmed by using healthy human epidermal keratinocytes (HEKa). Conclusion The gemini surfactant-based lipoplexes modified with p18-4 peptide showed significantly higher efficiency and safety compared to the system that did not contain a cancer targeting peptide and provided evidence for their potential application to achieve targeted melanoma gene therapy.

Shahin, H. I., B. P. Vinjamuri, A. A. Mahmoud, R. N. Shamma, S. M. Mansour, H. O. Ammar, M. M. Ghorab, M. B. Chougule, and L. Chablani, "Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension.", Journal of controlled release : official journal of the Controlled Release Society, vol. 302, pp. 126-139, 2019. Abstract

Pulmonary delivery of vasodilators is a promising alternative for the intravenous and oral treatment of pulmonary arterial hypertension (PAH). The aim of this study was to design and evaluate hydrogel microparticles as a carrier for sustained pulmonary delivery of sildenafil citrate. Spray dried hydrogel microparticles containing biodegradable sodium carboxymethyl cellulose, sodium alginate, and sodium hyaluronate polymers at variable concentrations were prepared. A design of experiment using the "Extreme Vertices Mixture" design was executed. The design was used to study the influence of polymer concentration and their interactions on the physicochemical properties of the formulations in terms of particle size, particle size distribution, product yield, entrapment efficiency, and in-vitro drug release. Selected formulations were also evaluated for swelling, biodegradation, moisture content, in-vitro aerodynamic performance, and cytotoxicity. In addition, a lung deposition and pharmacokinetic study was conducted in rats to study drug accumulation in lungs and blood after intratracheal administration of the spray dried inhalable hydrogel microparticles in comparison to orally administered Viagra®. The results demonstrated that formulated microparticles had a mean geometric particle size between 2 and 5 μm, entrapment efficiency of >80%, and yield ranging between 47 and 66% w/w. The in-vitro drug release profiles showed a sustained drug release of sildenafil citrate for over 24 h. The statistical design showed a significant influence of the microparticulate composition on the physicochemical properties. Furthermore, selected formulations were evaluated for their aerodynamic properties. The aerodynamic properties included fine particle fraction ranging between 24 and 30%, dose recovery percent of 68-8 5%, and average mass median aerodynamic diameter of 4.6-4.8 μm. The in-vivo pharmacokinetic study showed that inhaled spray dried hydrogel microparticles (M6) formulation had significantly higher lung/blood C, AUC, extended half-life, and mean residence time in comparison to orally administered sildenafil citrate of the same dose. In conclusion, the formulated drug-loaded spray dried hydrogel microparticles showed promising in-vitro and in-vivo results for the pulmonary delivery of sildenafil citrate. The spray dried hydrogel microparticles formulation can be considered as a potential alternative of oral sildenafil citrate for treatment of PAH.